Acorda Therapeutics has filed for bankruptcy protection, hoping to keep operating while it tries to arrange the sale of its main assets to a US subsidiary of Germany’s Mer
US specialist pharma company Acorda is to acquire Biotie for $363 million, a move which it hopes will make it a leader in Parkinson's disease treatments.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.